Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sulfadoxine/Pyrimethamine Dispersible Tablets vs G-COSPE®
NCT05497063Phase 1Unknown
- Sponsor
- Emzor Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of sulfadoxine + pyrimethamine in malaria (2 arms), sponsored by Emzor Pharmaceuticals. Primary endpoints: Peak Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Status: unknown.
02
Drugs
sulfadoxine + pyrimethamine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05497063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497063.